Skip to content

Effect of Equivalent Dose of Alfentanil and Sufentanil in Bronchoscopic Treatment

Effect of Equivalent Dose of Alfentanil and Sufentanil Combined With Remimazolam in Complex Bronchoscopic Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06414018
Acronym
EOEDSAAIBT
Enrollment
80
Registered
2024-05-14
Start date
2024-05-20
Completion date
2024-12-28
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of Drug

Keywords

Afentanil, sufentanil, bronchoscopy, Recovery time

Brief summary

The equivalent dose of sufentanil and afentanil combined with laryngeal mask was used for complex bronchoscopy to observe the intraoperative effect and the influence on the recovery of patients

Detailed description

Afentanil is a powerful, fast-acting narcotic analgesic, which can effectively inhibit intubation reflex. Compared with sufentanil, it has a short half-life and is safer, and can be used as the first choice for short surgical analgesics. In this study, by comparing the use of equivalent dose sufentanil and afentanil combined with laryngeal mask for complex bronchoscopy, the intraoperative analgesic effect and the influence on the recovery of patients were observed, and a better anesthesia scheme was provided for tracheoscopy.

Interventions

DRUGAlfentanil

alfentanil 10ug/kg is used for anesthesia induction

Sponsors

Xinxiang Central Hospital
CollaboratorOTHER
Tongji Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-80, * ASA I-III level; * BMI 18.5\ 23.9;

Exclusion criteria

* Patients with full stomach and high risk of reflux aspiration; * Allergic to benzodiazepines, opioids, rocuronium bromide; * Those who have taken sedative, analgesic or antidepressant drugs within 24 hours; * Pregnant and lactating women; * severe liver and kidney dysfunction; * Patients with severe anemia and hypoproteinemia; * Previous drug use history; * Recently participated in other clinical studies; * Patients who cannot cooperate with communication.

Design outcomes

Primary

MeasureTime frameDescription
time of Recovery1daythe time from the end of surgery to awake of patient

Secondary

MeasureTime frameDescription
Time records1 dayAnesthesia time, induction time, surgical time, awakening time and recovery time
dose of drugs1 dayThe total amount of sedative and analgesic drugs used.
rate of respiratory suppression incidence1 dayRespiratory frequency\<8 times/min or SP02\<90%
rate of Incidence of Treatment-Emergent Adverse Events1dayIntraoperative blood pressure and heart rate changes: record the patient's intraoperative blood pressure, heart rate, and the use of related vasoactive drugs; Postoperative adverse reactions: such as hypertension, hypotension, tachycardia, gastrointestinal symptoms, postoperative restlessness, etc

Other

MeasureTime frameDescription
rate of Postoperative adverse reaction1 dayAirway obstruction, hypoxemia, apnea, laryngeal spasm, bronchospasm, cough, postoperative nausea and vomiting, postoperative pain (VAS score), hypotension, bradycardia, dizziness

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026